instruction
stringlengths
33
156
input
float64
output
stringlengths
120
1.97k
Does Abatacept and Tasimelteon interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Tasimelteon can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tazarotene interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Tazarotene can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tazemetostat interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Tazemetostat can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tegaserod interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Tegaserod can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Telithromycin interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Telithromycin can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Temozolomide interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Temozolomide is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Temsirolimus interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Temsirolimus can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Teniposide interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates with a narrow therapeutic index. In short, The metabolism of Teniposide can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Tenofovir alafenamide interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Tenofovir alafenamide can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tenoxicam interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Tenoxicam can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Teprotumumab interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Teprotumumab, and the severity of the interaction is major.
Does Abatacept and Terbinafine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Terbinafine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Terfenadine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Terfenadine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Teriflunomide interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Teriflunomide, and the severity of the interaction is major.
Does Abatacept and Testosterone cypionate interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Testosterone cypionate can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Testosterone enanthate interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Testosterone enanthate can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Testosterone interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Testosterone can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tetrabenazine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Tetrabenazine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Thalidomide interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Thalidomide can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Theophylline interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Theophylline can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Thiopental interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates with a narrow therapeutic index. In short, The metabolism of Thiopental can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Thioridazine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Thioridazine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Thiotepa interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Thiotepa can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Thiothixene interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Thiothixene can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Ticagrelor interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Ticagrelor can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tick-borne encephalitis vaccine (whole virus, inactivated) interact?
null
Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Ticlopidine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Ticlopidine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Timolol interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Timolol can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tioguanine interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Tioguanine is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Tiotropium interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Tiotropium can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tipranavir interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Tipranavir can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tixocortol interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Tixocortol, and the severity of the interaction is major.
Does Abatacept and Tizanidine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Tizanidine can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Tocilizumab interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Tocilizumab, and the severity of the interaction is major.
Does Abatacept and Tofacitinib interact?
null
When combined with biologic drugs such as abatacept, tofacitinib may cause enhanced toxic effects such as an increased risk of serious systemic and local infection , . In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Tofacitinib, and the severity of the interaction is major.
Does Abatacept and Tolazamide interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Tolazamide can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tolbutamide interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Tolbutamide can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tolterodine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Tolterodine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tolvaptan interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Tolvaptan can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Topotecan interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Topotecan is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Torasemide interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Torasemide can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Trabectedin interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates with a narrow therapeutic index. In short, The metabolism of Trabectedin can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Tramadol interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Tramadol can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Trastuzumab emtansine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Trastuzumab emtansine can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Trastuzumab interact?
null
While trastuzumab treatment itself can cause neutropenia, its co-administration with other immunosuppressive agents has been shown to result in synergistic neutropenic effects. In randomized controlled clinical trials, patients receiving trastuzumab in combination with myelosuppressive chemotherapy had higher rates of moderate to severe neutropenia and febrile neutropenia compared to those receiving chemotherapy alone. The pathophysiologic basis for this exacerbation of neutropenia has not been determined. In short, The risk or severity of neutropenia can be increased when Trastuzumab is combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Trazodone interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Trazodone can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Treprostinil interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Treprostinil can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Tretinoin interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Tretinoin can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Triamcinolone interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Triamcinolone can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Triamterene interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Triamterene can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Triazolam interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Triazolam can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Triclabendazole interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Triclabendazole can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Trifluoperazine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Trifluoperazine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Trifluridine interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Trifluridine is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Trimethoprim interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Trimethoprim can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Trimipramine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates with a narrow therapeutic index. In short, The metabolism of Trimipramine can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Tucatinib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Tucatinib can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Typhoid Vaccine Live interact?
null
In most cases, the coadministration of live vaccines and immunosuppressive agents is contraindicated due to the risk of uncontrolled replication of the virus and subsequent infection. Drugs capable of causing clinically significant immunosuppression include chemotherapeutic agents (e.g. alkylating agents, antimetabolites), high-dose corticosteroids, and immune mediators/modulators (e.g. TNF-alpha inhibitors). In short, The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Typhoid vaccine interact?
null
Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Typhoid Vi polysaccharide vaccine interact?
null
Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Ublituximab interact?
null
Prescribing information for Briumvi (ublituximab-xiiy) states that its co-administration with immunosuppressants (e.g. immunosuppressive doses of corticosteroids) may increase the risk of infection. Ublituximab, a B-cell depleting agent, is itself an immunosuppressive medication - the co-administration of ublituximab with agents exerting a similar effect may therefore result in additive immunosuppression and a subsequent increase in the risk of developing an infection. In short, The risk or severity of infection can be increased when Ublituximab is combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Udenafil interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Udenafil can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Umeclidinium interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Umeclidinium can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Upadacitinib interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Upadacitinib, and the severity of the interaction is major.
Does Abatacept and Valbenazine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Valbenazine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Valdecoxib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Valdecoxib can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Valproic acid interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Valproic acid can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Valsartan interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Valsartan can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Vandetanib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vandetanib can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Vardenafil interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Vardenafil can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Varicella zoster vaccine (liveattenuated) interact?
null
In most cases, the coadministration of live vaccines and immunosuppressive agents is contraindicated due to the risk of uncontrolled replication of the virus and subsequent infection. Drugs capable of causing clinically significant immunosuppression include chemotherapeutic agents (e.g. alkylating agents, antimetabolites), high-dose corticosteroids, and immune mediators/modulators (e.g. TNF-alpha inhibitors). In short, The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Varicella zoster vaccine (recombinant) interact?
null
Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Vedolizumab interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Vedolizumab, and the severity of the interaction is major.
Does Abatacept and Vemurafenib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vemurafenib can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Venetoclax interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Venetoclax can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Venlafaxine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Venlafaxine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Verapamil interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Verapamil can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Vernakalant interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Vernakalant can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Vibrio cholerae CVD 103-HgR strain live antigen interact?
null
High doses of immunosuppressive agents, such as antimetabolites, alkylating agents, cytotoxic drugs, and corticosteroids in combination with the cholera vaccine may reduce the immune response to the vaccine. In short, The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Abatacept, and the severity of the interaction is minor.
Does Abatacept and Vilanterol interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Vilanterol, and the severity of the interaction is major.
Does Abatacept and Vilazodone interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Vilazodone can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Vinblastine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vinblastine can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Vincristine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vincristine can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Vindesine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vindesine can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Vinflunine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vinflunine can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Vinorelbine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Vinorelbine can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Voclosporin interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Voclosporin, and the severity of the interaction is major.
Does Abatacept and Vonoprazan interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Vonoprazan can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Vorapaxar interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Vorapaxar can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Voriconazole interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Voriconazole can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Vorinostat interact?
null
Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Vorinostat, and the severity of the interaction is major.
Does Abatacept and Vortioxetine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Vortioxetine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Voxelotor interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Voxelotor can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Warfarin interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Warfarin can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Yellow fever vaccine interact?
null
In most cases, the coadministration of live vaccines and immunosuppressive agents is contraindicated due to the risk of uncontrolled replication of the virus and subsequent infection. Drugs capable of causing clinically significant immunosuppression include chemotherapeutic agents (e.g. alkylating agents, antimetabolites), high-dose corticosteroids, and immune mediators/modulators (e.g. TNF-alpha inhibitors). In short, The risk or severity of infection can be increased when Yellow fever vaccine is combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Yohimbine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Yohimbine can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Zafirlukast interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Zafirlukast can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Zaleplon interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Zaleplon can be increased when combined with Abatacept, and the severity of the interaction is moderate.
Does Abatacept and Zanubrutinib interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates with a narrow therapeutic index. In short, The metabolism of Zanubrutinib can be increased when combined with Abatacept, and the severity of the interaction is major.
Does Abatacept and Zidovudine interact?
null
The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Zidovudine can be increased when combined with Abatacept, and the severity of the interaction is moderate.